LMR Partners’s Xeris Biopharma Holdings XERS Stock Holding History

LMR Partners’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-107,355	Closed	-$275K	–	1488
2022 Q1	$275K	Buy	+107,355	New	+$262K	﹤0.01%	1097

Other funds holding XERS

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

LMR Partners's XERS Position: Q2 2022 in Review

LMR Partners sold out of Xeris Biopharma Holdings (XERS) in Q2 2022, closing a stake of 107,355 shares — an estimated $275K sold.

LMR Partners first reported a position in XERS in Q1 2022 and held it in 1 quarter. The position peaked at $275K in Q1 2022. 103 funds tracked by Wall St. Rank hold XERS as of Q2 2022.

LMR Partners reported no remaining Xeris Biopharma Holdings position as of Q2 2022 after selling out during the quarter.
LMR Partners sold 107,355 Xeris Biopharma Holdings shares in Q2 2022, an estimated $275K.
LMR Partners first reported a position in Xeris Biopharma Holdings in Q1 2022 and held it in 1 quarter.
LMR Partners's Xeris Biopharma Holdings position peaked at $275K in Q1 2022.
103 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2022.

Based on LMR Partners's 13F filing for Q2 2022, filed 15 Aug 2022.